TITLE

World Briefs

PUB. DATE
August 2008
SOURCE
Pharmaceutical Technology;Aug2008, Vol. 32 Issue 8, p22
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers world news briefs related to pharmaceutical industry. In Asia and Pacific, NovaMed Pharmaceuticals (Shanghai) and Pfizer China has formed a partnership in the oncology area in distributing oncology products throughout mainland China. In Europe, an agreement is made between DSM Biologics in Heerlen, Netherlands and Crucell in Leiden, Netherlands with contract manufacturer Avid Bioservices for the licensing of the PER.C6 located in the U.S.
ACCESSION #
34001111

 

Related Articles

  • DSM Biologics and Crucell Enter Licensing Deal. Bryner, Michelle // Chemical Week;8/1/2007, Vol. 169 Issue 26, p19 

    The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...

  • DSM and Crucell license antibody technology to Sartorius.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p16 

    The article reports on the licensing agreement accorded by DSM Biologics and Crucell NV with Sartorius Biotech GmbH. The two companies have agreed to a non-exclusive PER.C6 research licensing deal with Sartorius. In addition, Sartorius will use Crucell's key technology to assess monoclonal...

  • News Watch.  // European Chemical News;6/6/2005, Vol. 82 Issue 2150, p25 

    Presents news briefs concerning pharmaceutical industry as of June 2005. Research agreement signed by Codexis with Bristol-Myers Squibb to improve biocatalyst activity for a new Bristol-Myers Squibb candidate; Commercial license agreement signed by Crucell and DSM Biologics with Ferring...

  • MorphoSys Signs Cooperative Agreements.  // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p166 

    The article announces the license agreement signed by MorphoSys AG with Crucell NV and DSM Biologics. The agreement allows the former to use a cell line designed to produce clinical-grade material and develop its therapeutic human antibody program. The financial details of these agreements were...

  • Pharmaceuticals & fine chemicals.  // Chemical Week;1/1/2003, Vol. 165 Issue 1, p33 

    Presents news briefs on the chemical industry as of January 1, 2003. License deal signed by DSM Biologics with Crucell; Acquisition of the patents of Novozymes relating to the production of a recombinant enzyme for pharmaceutical applications by Solvay.

  • Collaborations: DSM Biologics and Crucell Announce Licensing Deal with LFB Biotechnologies.  // Pharmaceutical Technology;Sep2007, Vol. 31 Issue 9, p134 

    The article reports that DSM Biologics of New Jersey and the biotechnology company Crucell NV of the Netherlands has signed a nonexclusive research licensing agreement with LFB Biotechnologies of Paris, France. It is stated that the LFB will use the PER.C6 production technology of Crucell to...

  • Crucell signs licensing deal. Tyler, Alan // European Chemical News;6/14/2004, Vol. 80 Issue 2104, p29 

    Reports on the research licensing deal signed by Dutch biotechnology player Crucell with PanGenetics. Significance of the deal to PanGenetics; Payment and annual maintenance fees to be received by Crucell and DSM Biologics; Description made by PanGenetics on itself.

  • Biotech milestonc.  // Chemical Engineering;Nov2008, Vol. 115 Issue 12, p16 

    The article reports that a joint venture between DSM Biologics and Crucell NV has been scaled up to 250 L by DSM Biologics scientists at its GMP facility in Groningen, Netherlands. Accordingly , the researchers achieved 8g/L for an immunoglobulin being expressed by cells using the chemically...

  • Pharma CAPSULES.  // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p106 

    The article offers news briefs related to the pharmaceutical industry. A new facility called PERCIVIA PER.C6 Development Center was opened by biotechnology company Crucell NV and technology partner DSM Biologics. A high-speed packaging line is planned by contract manufacturer Surefil LLC to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics